tirzepatide glp1 and gip is a first-in-class dual agonist targeting both GLP-1 receptors, offering a powerful and synergistic approach to glycaemic control and weight management., By acting on multiple Tirzepatide 10mg — Dual Receptor

This information is for educational purposes only

Quote: " The litigation is growing

Key efficacy results: - Up to 12.2% weight loss from baseline (26.6 lbs) at the highest dose - Up to 10.9% placebo-adjusted weight loss - Statistically significant, dose-dependent weight loss across all dose cohorts - Weight loss was progressive from Week 1 through Week 13 with no plateau observed - Significant differences versus placebo were observed for all doses above 15 mg starting at Week 1 Why "no plateau" matters: Most GLP-1 drugs show a weight loss plateau at some point the body adapts and weight loss slows

The day after the announcement, the top lawyer for the Department of Health and Human Services, Mike Stuart, announced on X that his office had referred Hims & Hers to the Justice Department for potential violations of the Federal Food, Drug and Cosmetic Act, which regulates the sale of medications

Carriers justifiably worry about anything that might increase their plans premium which leads healthier members to leave, causing a spiral of increasing premiums and decreasing (and sicker) membership